Sign in

    Odysseas Manesiotis

    Research Analyst at Berenberg

    Odysseas Manesiotis is an Equity Research Analyst at Berenberg, specializing in coverage of the telecommunications and media sectors. He has been responsible for analyzing and publishing investment recommendations on companies such as STRATEC Biomedical Systems AG, where he has demonstrated strong performance with notable upgrades and consistently targeted outperformance. Manesiotis joined Berenberg prior to 2025, having previously gained experience at other firms and is now recognized for delivering detailed coverage of key names and providing actionable insights in his sector. He has worked under regulatory authorities such as the UK Financial Conduct Authority and BaFin in Germany, though specific securities licenses are not publicly listed.

    Odysseas Manesiotis's questions to QIAGEN (QGEN) leadership

    Odysseas Manesiotis's questions to QIAGEN (QGEN) leadership • Q3 2024

    Question

    Odysseas Manesiotis asked for details on QIAstat instrument placements, including competitive wins and the mix of reagent rentals, and questioned the capital deployment strategy regarding M&A versus share buybacks.

    Answer

    CEO Thierry Bernard reported over 150 QIAstat placements in Q3, driven by a newly competitive menu in the U.S., with a placement-to-capital-sale mix of roughly 50/50. Regarding capital deployment, Bernard stated that QIAGEN is active on both M&A and buybacks, remaining committed to its $1 billion shareholder return plan by 2028 while actively seeking value-accretive acquisitions.

    Ask Fintool Equity Research AI